Vol 8, No 4 (2012)
Case report
Published online: 2012-10-08
Response to third line hormonotherapy (fulvestrant) in patient with metastatic breast cancer after the f
Onkol. Prak. Klin 2012;8(4):151-154.
Abstract
Hormonotherapy is an effective palliative treatment in patients with metastatic, hormone-dependent breast
cancer, which improves the quality of life of these patients. Next line hormonotherapy is considered to be
reasonable in the case of good efficacy of primary hormonal treatment. Clinical observations indicate the
potential benefit of returning to the hormonotherapy even if the first line fails. The paper presents a case
of a patient who has achieved long-term clinical response to therapy with fulvestrant, despite the failure
of treatment with aromatase inhibitors.
cancer, which improves the quality of life of these patients. Next line hormonotherapy is considered to be
reasonable in the case of good efficacy of primary hormonal treatment. Clinical observations indicate the
potential benefit of returning to the hormonotherapy even if the first line fails. The paper presents a case
of a patient who has achieved long-term clinical response to therapy with fulvestrant, despite the failure
of treatment with aromatase inhibitors.